



TPG Asia VII SF Pte Ltd
Registration Number: 201724102G

Annual Report
Year ended 31 December 2020

Directors' statement

We are pleased to submit this annual report to the members of the Company together with the audited financial statements for the financial year ended 31 December 2020.

In our opinion:

- (a) the financial statements set out on pages FS1 to FS31 are drawn up so as to give a true and fair view of the financial position of the Company as at 31 December 2020 and the financial performance, changes in equity and cash flows of the Company for the year ended on that date in accordance with the provisions of the Singapore Companies Act, Chapter 50 and Singapore Financial Reporting Standards; and
- (b) at the date of this statement, having regard to the financial support given by the ultimate holding company, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

The Board of Directors has, on the date of this statement, authorised these financial statements for issue.

Directors

The directors in office at the date of this statement are as follows:

Lee Wei Sheng
Dominic John Picone
Nicholas James Kay
Seow Yung Liang Richard
Zubin Jamshed Irani (Alternate to Lee Wei Sheng)
David Tan Wei Ming

Directors' interests

According to the register kept by the Company for the purposes of Section 164 of the Companies Act, Chapter 50 (the Act), no director who held office at the end of the financial year (including those held by their spouses and infant children) had interests in shares, debentures, warrants or share options of the Company, or of related corporations, either at the beginning or at the end of the financial year.

Neither at the end of, nor at any time during the financial year, was the Company a party to any arrangement whose objects are, or one of whose objects is, to enable the directors of the Company to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate.

Share options

During the financial year, there were:

- (i) no options granted by the Company to any person to take up unissued shares in the Company; and
- (ii) no shares issued by virtue of any exercise of option to take up unissued shares of the Company.

As at the end of the financial year, there were no unissued shares of the Company under option.

Auditors

The auditors, KPMG LLP, have indicated their willingness to accept re-appointment.

On behalf of the Board of Directors



Dominic John Picone
Director



Nicholas James Kay
Director

27 August 2021



KPMG LLP
16 Raffles Quay #22-00
Hong Leong Building
Singapore 048581

Telephone +65 6213 3388
Fax +65 6225 0984
Internet www.kpmg.com.sg

Independent auditors' report

Members of the Company
TPG Asia VII SF Pte Ltd

Report on the audit of the financial statements

Opinion

We have audited the financial statements of TPG Asia VII SF Pte Ltd (the "Company"), which comprise the statement of financial position as at 31 December 2020, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, as set out on pages FS1 to FS31.

In our opinion, the accompanying financial statements are properly drawn up in accordance with the provisions of the Companies Act, Chapter 50 (the "Act") and Financial Reporting Standards in Singapore ("FRSs") so as to give a true and fair view of the financial position of the Company as at 31 December 2020 and of the financial performance, changes in equity and cash flows of the Company for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with Singapore Standards on Auditing ("SSAs"). Our responsibilities under those standards are further described in the "*Auditors' responsibilities for the audit of the financial statements*" section of our report. We are independent of the Company in accordance with the Accounting and Corporate Regulatory Authority *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* ("ACRA Code") together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

Management is responsible for the other information contained in the annual report. Other information is defined as all information in the annual report other than the financial statements and our auditors' report thereon.

We have obtained all other information prior to the date of this auditors' report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and directors for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and FRSs, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Company's financial reporting process.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

Report on other legal and regulatory requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.



KPMG LLP
Public Accountants and
Chartered Accountants

Singapore

27 August 2021

Statement of financial position
As at 31 December 2020

	Note	2020 US\$'000	2019 US\$'000
Assets			
Investments at fair value through profit or loss	4	4,884,872	3,381,999
Non-current assets		<u>4,884,872</u>	<u>3,381,999</u>
Amounts due from related parties	5	25,137	19,959
Shareholder loan receivable	6	2,745	2,745
Cash and cash equivalents		5,196	5,553
Current assets		<u>33,078</u>	<u>28,257</u>
Total assets		<u>4,917,950</u>	<u>3,410,256</u>
Equity			
Share capital	7	3,328,458	2,998,956
Accumulated profits		1,120,148	389,940
Total equity		<u>4,448,606</u>	<u>3,388,896</u>
Liabilities			
Deferred tax liabilities	8	36,748	–
Non-current liabilities		<u>36,748</u>	<u>–</u>
Amounts due to related parties	5	29,926	21,251
Shareholder loans payable	6	401,693	–
Other payables		319	109
Accrued expenses		658	–
Current liabilities/Total liabilities		<u>432,596</u>	<u>21,360</u>
Total equity and liabilities		<u>4,917,950</u>	<u>3,410,256</u>

The accompanying notes form an integral part of these financial statements.

Statement of comprehensive income
Year ended 31 December 2020

	Note	2020	2019
		US\$'000	US\$'000
Investment income			
Net gain on financial assets at fair value through profit or loss:			
- Net change in fair value of investments		672,391	304,253
- Net gain on disposal of investment		22,904	4,278
- Interest income		–	101
- Dividend income		76,272	510
Net investment income		<u>771,567</u>	<u>309,142</u>
Unrealised foreign exchange (loss)/gain		(278)	118
Total income		<u>771,289</u>	<u>309,260</u>
Operating expenses			
Management fees		(3,174)	(2,455)
Professional fees		(625)	(991)
Other expenses		(534)	(183)
Total operating expenses		<u>(4,333)</u>	<u>(3,629)</u>
Profit before tax		766,956	305,631
Tax expense	9	<u>(36,748)</u>	–
Profit for the year/Total comprehensive income for the year		<u>730,208</u>	<u>305,631</u>

The accompanying notes form an integral part of these financial statements.

Statement of changes in equity
Year ended 31 December 2020

	Share capital US\$'000	Accumulated profits US\$'000	Total US\$'000
At 1 January 2019	*	84,309	84,309
Total comprehensive income for the year			
Profit for the year	–	305,631	305,631
Total comprehensive income for the year	–	305,631	305,631
Transactions with owners, recognised directly in equity			
Issuance of shares	3,046,017	–	3,046,017
Redemption of shares	(47,061)	–	(47,061)
Total transactions with owners	2,998,956	–	2,998,956
At 31 December 2019	2,998,956	389,940	3,388,896
At 1 January 2020	2,998,956	389,940	3,388,896
Total comprehensive income for the year			
Profit for the year	–	730,208	730,208
Total comprehensive income for the year	–	730,208	730,208
Transactions with owners, recognised directly in equity			
Issuance of shares	329,502	–	329,502
Total transactions with owners	329,502	–	329,502
At 31 December 2020	3,328,458	1,120,148	4,448,606

* Denotes less than \$1,000

The accompanying notes form an integral part of these financial statements.

Statement of cash flows
Year ended 31 December 2020

	Note	2020 US\$'000	2019 US\$'000
Cash flow from operating activities			
Profit for the year		766,956	305,631
Adjustments for:			
Net gain on financial assets at fair value through profit or loss:			
- Net change in fair value of investments		(672,391)	(304,253)
- Net gain on disposal of investment		(22,904)	(4,278)
- Interest income		-	(101)
- Dividend income		(76,272)	(510)
		<u>(4,611)</u>	<u>(3,511)</u>
Changes in operating assets and liabilities:			
Other payables		210	(3,648)
Amounts due from related parties	5	(5,178)	19,497
Amounts due to related parties	5	8,675	(11,059)
Other receivables		-	387
Accrued expenses		658	(275)
Net cash (used in)/from operating activities		<u>(246)</u>	<u>1,391</u>
Cash flows from investing activities			
Purchase of investments		(939,030)	(1,060,142)
Proceeds from disposal of investments		131,452	24,823
Interest income		-	101
Dividend received		76,272	510
Net cash used in investing activities		<u>(731,306)</u>	<u>(1,034,708)</u>
Cash flows from financing activities			
Proceeds from/(Settlement of) loan due to shareholder	6	401,693	(1,961,230)
Disbursement of loan due from shareholder		-	(2,745)
Proceeds from issuance of shares		329,502	3,046,017
Settlement of redemption of shares		-	(47,061)
Net cash from financing activities		<u>731,195</u>	<u>1,034,981</u>
Net (decrease)/increase in cash and cash equivalents		(357)	1,664
Cash and cash equivalents at beginning of the year		5,553	3,889
Cash and cash equivalents at end of the year		<u>5,196</u>	<u>5,553</u>

The accompanying notes form an integral part of these financial statements.

Notes to the financial statements

These notes form an integral part of the financial statements.

The financial statements were authorised for issue by the Board of Directors on 27 August 2021.

1 Domicile and activities

TPG Asia VII SF Pte Ltd (the “Company”) is incorporated in the Republic of Singapore and has its registered office at 83 Clemenceau Avenue, #11-01 UE Square, Singapore 239920.

The principal activities of the Company are those relating to long term investment holding activities.

The immediate holding company of the company during the financial year is TPG Asia VII Finance, L.P. registered in Prince Edward Island, Canada. The ultimate holding company of the company during the financial year is TPG Asia GenPar VII, L.P., registered in Grand Cayman, Cayman Islands.

2 Basis of preparation

2.1 Statement of compliance

The financial statements have been prepared in accordance with the Singapore Financial Reporting Standards (“FRS”). The changes to significant accounting policies are described in note 2.6.

2.2 Going concern basis

At the reporting date, the Company’s current liabilities exceed its current assets by US\$399,518,000. The financial statements have been prepared on the going concern basis which assumes that the Company will continue in operational existence for the foreseeable future. The validity of this assumption depends on the continued support of the Company’s ultimate holding company. Management is of the opinion that this support will be forthcoming over the next twelve months and therefore believes that it is appropriate for the financial statements to be prepared on a going concern basis.

2.3 Basis of measurement

The financial statements have been prepared on a historical cost basis, except where otherwise indicated in the accounting policies set out below.

2.4 Functional and presentation currency

The financial statements are presented in United States dollars (“USD” or “US\$”), which is the Company’s functional currency. All financial information presented in USD have been rounded to the nearest thousands, unless otherwise stated.

2.5 Use of estimates and judgements

The preparation of the financial statements in conformity with FRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in Note 3.1, Note 3.4, Note 4 and Note 13.

Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

The Company has an established control framework with respect to the measurement of fair values. This includes a valuation team that has overall responsibility for all significant fair value measurements, including Level 3 fair values, and reports directly to the management.

The valuation team regularly reviews significant unobservable inputs and valuation adjustments. If third party information is used to measure fair values, then the valuation team assesses and documents the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of FRS, including the level in the fair value hierarchy in which such valuations should be classified.

Significant valuation issues are reported to the Board of Directors.

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as described in Note 13.

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement (with Level 3 being the lowest).

The Company recognises transfers between levels of the fair value hierarchy as of the end of the reporting period during which the change has occurred.

Further information about the assumptions made in measuring fair values is included in Note 13.

2.6 Changes in accounting policies

New standards and amendments

The Company has applied the following FRSs, amendments to and interpretations of FRS for the first time for the annual period beginning on 1 January 2020:

- *Amendments to References to Conceptual Framework in FRS Standards*
- *Definition of a Business* (Amendments to FRS 103)
- *Definition of Material* (Amendments to FRS 1 and FRS 8)
- *Interest Rate Benchmark Reform* (Amendments to FRS 109, FRS 39 and FRS 107)

The adoption of these FRSs, amendments to standards and interpretations did not have a material effect on the Company's financial statements and the Company's statement of financial position.

3 Significant accounting policies

The accounting policies set out below have been applied consistently to the all periods presented in these financial statements.

3.1 Investment entity

The Company is an investment entity and measures its controlled subsidiary investments at fair value through profit or loss. In determining whether the Company meets the definition of an investment entity, management considered the business purpose and structure of the Company as a whole. The Company has been deemed to meet all the essential elements of the definition of an investment entity as it:

- obtains funds for the purpose of providing investors with professional investment management services;
- manages the investment portfolio on a fair value basis; and
- seeks to invest for capital appreciation and investment income.

An investment entity is also expected to typically have the following characteristics:

- holds more than one investment;
- has more than one investor;
- has investors that are not related parties; and
- has ownership interests in the form of equity or similar interests.

Although the Company has only one investor that is a related party, it is part of an umbrella fund structure where there are multiple ultimate investors that are not related parties. As the Company also meets the other aforementioned characteristics, management has deemed that the Company meets the definition of an investment entity. Consequently, management concluded that the Company should not consolidate the subsidiaries which do not provide investment-related services but measure the investments in such subsidiaries at fair value through profit or loss.

3.2 Foreign currency transactions

Transactions in foreign currencies are translated to the functional currency of the Company entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortised cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortised cost in foreign currency translated at the exchange rate at the end of the year.

Foreign currency differences arising on the translation are recognised in profit or loss.

3.3 Financial instruments

(i) Recognition and initial measurement

Non-derivative financial assets and financial liabilities

Trade receivables and debt investments issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset (unless it is a trade receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

(ii) Classification and subsequent measurement

Non-derivative financial assets

On initial recognition, a financial asset is classified as measured at: amortised cost; fair value through FVOCI – debt investment; FVOCI – equity investment; or FVTPL.

Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting year following the change in the business model.

Financial assets at amortised cost

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Debt investments at FVOCI

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Equity investments at FVOCI

On initial recognition of an equity investment that is not held-for-trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI. This election is made on an investment-by-investment basis.

Financial assets at FVTPL

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- how the performance of the portfolio is evaluated and reported to the Company's management;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- how managers of the business are compensated – e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected; and
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held-for-trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Non-derivative financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, ‘principal’ is defined as the fair value of the financial asset on initial recognition. ‘Interest’ is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable rate features;
- prepayment and extension features; and
- terms that limit the Company’s claim to cash flows from specified assets (e.g. non-recourse features).

A prepayment feature is consistent with the solely payments of principal and interest criterion if the prepayment amount substantially represents unpaid amounts of principal and interest on the principal amount outstanding, which may include reasonable additional compensation for early termination of the contract. Additionally, for a financial asset acquired at a significant discount or premium to its contractual par amount, a feature that permits or requires prepayment at an amount that substantially represents the contractual par amount plus accrued (but unpaid) contractual interest (which may also include reasonable additional compensation for early termination) is treated as consistent with this criterion if the fair value of the prepayment feature is insignificant at initial recognition.

Non-derivative financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Debt investments at FVOCI

These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.

Equity investments at FVOCI

These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are never reclassified to profit or loss.

Non-derivative financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Directly attributable transaction costs are recognised in profit or loss as incurred.

Other financial liabilities are initially measured at fair value less directly attributable transaction costs. They are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. These financial liabilities comprise amounts due to related parties, shareholder loan payables, other payables and accrued expenses.

(iii) Derecognition

Financial assets

The Company derecognises a financial asset when:

- the contractual rights to the cash flows from the financial asset expire; or
- it transfers the rights to receive the contractual cash flows in a transaction in which either:
 - substantially all of the risks and rewards of ownership of the financial asset are transferred;
 - or
 - the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset.

Transferred assets are not derecognised when the Company enters into transactions whereby it transfers assets recognised in its statement of financial position, but retains either all or substantially all of the risks and rewards of the transferred assets.

Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire. The Company also derecognises a financial liability when its terms are modified and the cash flows of the modified liability are substantially different, in which case a new financial liability based on the modified terms is recognised at fair value.

On derecognition of a financial liability, the difference between the carrying amount extinguished and the consideration paid (including any non-cash assets transferred or liabilities assumed) is recognised in profit or loss.

(iv) Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

(v) Cash and cash equivalents

Cash and cash equivalents comprise cash balances.

(vi) Derivative financial instruments

Derivatives are initially measured at fair value and any directly attributable transaction costs are recognised in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are generally recognised in profit or loss.

(vii) Compound financial instruments

Compound financial instruments issued by the Company comprise convertible notes denominated in Singapore dollars that can be converted to ordinary shares at the option of the holder, where the number of shares to be issued is fixed and does not vary with changes in fair value.

The liability component of a compound financial instrument is initially recognised at the fair value of a similar liability that does not have an equity conversion option. The equity component is initially recognised at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortised cost using the effective interest method. The equity component of a compound financial instrument is not remeasured.

Interest related to the financial liability is recognised in profit or loss. On conversion at maturity, the financial liability is reclassified to equity and no gain or loss is recognised.

(viii) Share capital

Ordinary shares

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares are recognised as a deduction from equity, net of any tax effects.

3.4 Impairment

Non-derivative financial assets

The Company recognises loss allowances for expected credit losses (“ECLs”) on financial assets measured at amortised cost.

Loss allowances of the Company are measured on either of the following bases:

- 12-month ECLs: these are ECLs that result from default events that are possible within the 12 months after the reporting date (or for a shorter period if the expected life of the instrument is less than 12 months); or
- Lifetime ECLs: these are ECLs that result from all possible default events over the expected life of a financial instrument or contract asset.

General approach

The Company applies the general approach to provide for ECLs on all financial instruments. Under the general approach, the loss allowance is measured at an amount equal to 12-month ECLs at initial recognition.

At each reporting date, the Company assesses whether the credit risk of a financial instrument has increased significantly since initial recognition. When credit risk has increased significantly since initial recognition, loss allowance is measured at an amount equal to lifetime ECLs.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Company's historical experience and informed credit assessment and includes forward-looking information.

If credit risk has not increased significantly since initial recognition or if the credit quality of the financial instruments improves such that there is no longer a significant increase in credit risk since initial recognition, loss allowance is measured at an amount equal to 12-month ECLs.

The Company considers a financial asset to be in default when the customer is unlikely to pay its contractual obligations to the Company in full, without recourse by the Company to actions such as realising security (if any is held).

The maximum period considered when estimating ECLs is the maximum contractual period over which the Company is exposed to credit risk.

Measurement of ECLs

ECLs are probability-weighted estimates of credit losses. Credit losses are measured at the present value of all cash shortfalls (i.e. the difference between the cash flows due to the entity in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

Credit-impaired financial assets

At each reporting date, the Company assesses whether financial assets carried at amortised cost and debt investments at FVOCI are credit-impaired. A financial asset is 'credit-impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- a breach of contract such as a default;
- the restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;
- it is probable that the borrower will enter bankruptcy or other financial reorganisation; or
- the disappearance of an active market for a security because of financial difficulties.

Presentation of allowance for ECLs in the statement of financial position

Loss allowances for financial assets measured at amortised cost and contract assets are deducted from the gross carrying amount of these assets.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

3.5 Finance income and finance costs

The Company's finance income and finance costs include:

- interest income;
- interest expense;
- dividend income;
- the net gain or loss on financial assets at FVTPL; and
- the foreign currency gain or loss on financial assets and financial liabilities.

Interest income or expense is recognised using the effective interest method. Dividend income is recognised in profit or loss on the date on which the Company's right to receive payment is established.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to:

- the gross carrying amount of the financial asset; or
- the amortised cost of the financial liability.

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability. However, for financial assets that have become credit-impaired subsequent to initial recognition, interest income is calculated by applying the effective interest rate to the amortised cost of the financial asset. If the asset is no longer credit-impaired, then the calculation of interest income reverts to the gross basis.

Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognised in profit or loss using the effective interest method.

3.6 Tax

Tax expense comprises current and deferred tax. Current tax and deferred tax are recognised in profit or loss except to the extent that it relates to items recognised directly in equity or in other comprehensive income.

The Company has determined that interest and penalties related to income taxes, including uncertain tax treatments, do not meet the definition of income taxes, and therefore accounted for them under FRS 37 *Provisions, Contingent Liabilities and Contingent Assets*.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received that reflects uncertainty related to income taxes, if any.

Current tax assets and liabilities are offset only if certain criteria are met.

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognised for:

- temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss; and
- temporary differences related to investments in subsidiaries to the extent that the Company is able to control the timing of the reversal of the temporary difference and it is probable that they will not reverse in the foreseeable future.

The measurement of deferred taxes reflects the tax consequences that would follow the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.

Deferred tax assets and liabilities are offset if there is legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

Deferred tax assets are recognised for unused tax losses, unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Future taxable profits are determined based on the reversal of relevant taxable temporary differences. If the amount of taxable temporary differences is insufficient to recognise a deferred tax asset in full, then future taxable profits, adjusted for reversals of existing temporary differences, are considered, based on the business plans for individual subsidiaries in the Company. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

In determining the amount of current and deferred tax, the Company takes into account the impact of uncertain tax positions and whether additional taxes and interest may be due. The Company believes that its accruals for tax liabilities are adequate for all open tax years based on its assessment of many factors including interpretations of tax law and prior experience. This assessment relies on estimates and assumptions and may involve a series of multifaceted judgements about future events. New information may become available that causes the Company to change its judgement regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact tax expense in the year that such a determination is made.

3.7 New standards and interpretations not adopted

A number of new standards, interpretations and amendments to standards are effective for annual periods beginning after 1 January 2020 and earlier application is permitted; however, the Company has not early adopted the new or amended standards and interpretations in preparing these financial statements.

The new FRSs, interpretations and amendments to FRSs are not expected to have a significant impact on the Company's financial statements.

4 Investments at fair value through profit or loss

	2020	2019
	US\$'000	US\$'000
Investments at fair value through profit or loss		
Equity investments	<u>4,884,872</u>	<u>3,381,999</u>

Investments at fair value through profit or loss comprise indirect equity investment in the following projects:

- 1) Du Xiaoman, financial services business in consumer lending, wealth management, and payment based in Beijing, China;
- 2) Five Star, a small business finance company based in Chennai, India;
- 3) Greencross, a pet care company based in Australia;
- 4) Hangzhou Kangji Medical, a domestic manufacturer of Medical products based in Hangzhou, China;
- 5) Jaywalk Media, leading integrated artist management and drama production company based in Beijing, China;
- 6) Jetanin, a fertility specialist centre based in Thailand;
- 7) PAMEL/Apollo, a telecommunications tower company based in Myanmar;
- 8) Pathology Asia Holdings, independent pathology service provider based in Singapore;
- 9) Project Hostel, a hotel services provider based in Beijing, China;

- 10) RR Kabel, a housing wire and low voltage cable manufacturer based in India;
- 11) Sai Life Sciences, pure-play contract development and manufacturing company based in Hyderabad, India;
- 12) APM Monaco Limited, a jewellery company focused on the entry-luxury segment based in Hong Kong;
- 13) Dream Cruises, a premium cruise shipping company based in Hong Kong;
- 14) UPL Corporation, an agrochemicals company based in Mumbai, India;
- 15) Aviva Singlife, a life insurance company based in Singapore;
- 16) Jio Platforms Limited, a wireless and wireline broadband services company based in Ahmedabad, India;
- 17) Reliance Retail Ventures, a retail company focused on grocery, fashion, lifestyle, and consumer electronics, based in Mumbai, India;
- 18) Shanghai Bio-heart Biological Technology, a medical technology company based in Shanghai, China; and
- 19) Zhaoke Ophthalmology, and ophthalmology drug developer and manufacturer based in Guangzhou, China.

Investments at fair value through profit or loss also comprise the following unconsolidated subsidiary corporations:

Name of subsidiary corporation	Principal place of business	Ownership interest	
		2020 %	2019 %
TPG Keyhole L.P.	Cayman	82.95	82.95
Keyhole Holding Limited	Cayman	82.95	82.95
TPG Keyhole Success Holding Pte. Ltd.	Singapore	–	82.95
TPG Helipad, L.P.	Cayman	99.13	99.13
TPG Animation, L.P.	Cayman	76.47	76.47
Animation Holdings Limited	Cayman	67.37	62.55
TPG Upswing Ltd.	Cayman	59.58	59.58

The carrying value of these investments are set out as follows:

Investment	Type	Level	2020		2019	
			Cost US\$'000	Fair value US\$'000	Cost US\$'000	Fair value US\$'000
APM Monaco	Equity	Level 3	133,228	162,865	98,981	97,842
Aviva Singlife	Equity	Level 3	223,401	229,693	–	–
Dream Cruises	Equity	Level 3	180,915	30,400	164,861	164,841
Du Xiaoman	Equity	Level 3	775,000	985,194	775,000	845,623
Five Star	Equity	Level 3	156,792	226,900	156,792	202,100
Greencross	Equity	Level 3*	182,925	448,480	182,925	181,609
Kangji Medical Holdings	Equity	Level 1 [^]	170,622	347,384	189,317	253,472
Jaywalk Studio Ltd.	Equity	Level 3	201,478	168,511	199,500	199,500
Jetanin	Equity	Level 3	130,470	146,664	130,470	126,102
Jio Platforms Limited	Equity	Level 3	325,155	325,155	–	–
PAMEL/Apollo	Equity	Level 3	219,481	297,800	219,481	274,900
Pathology Asia Holdings	Equity	Level 3	199,634	467,940	199,634	266,600
Project Hostel	Equity	Level 3	84,535	90,744	83,735	82,910
Reliance Retail Ventures	Equity	Level 3	250,842	250,842	–	–
RR Kabel	Equity	Level 3	88,499	81,400	88,499	91,700
Sai Life Sciences	Equity	Level 3	140,718	206,300	140,718	155,400
Shanghai Bio-heart Biological Technology	Equity	Level 3	45,000	45,000	–	–
UPL Corporation	Equity	Level 3	274,184	338,600	357,484	439,400
Zhaoke Ophthalmology	Equity	Level 3	35,000	35,000	–	–
			<u>3,817,879</u>	<u>4,884,872</u>	<u>2,987,397</u>	<u>3,381,999</u>

* Greencross transferred from Level 2 to Level 3 in 2019 because observable market data were no longer available.

[^] Kangji Medical Holdings transferred from Level 3 to Level 1 in 2020 as the portfolio company is now traded in public markets.

5 Amounts due from/to related parties

	2020 US\$'000	2019 US\$'000
Amounts due from related parties, non-trade	<u>25,137</u>	<u>19,959</u>
Amounts due to related parties, non-trade	<u>29,926</u>	<u>21,251</u>

Non-trade amounts due from/to related parties are unsecured, interest-free, and repayable on demand. None of the receivables are past due. There is no allowance for doubtful debts arising from these outstanding balances.

The Company's exposure to credit and currency risks, and impairment losses for amounts due from related parties are disclosed in Note 12.

6 Shareholder loans receivable/payable

	2020	2019
	US\$'000	US\$'000
Shareholder loan receivable	2,745	2,745
Shareholder loans payable	401,693	–

The shareholder loans receivable/payable amounts are unsecured, interest-free and repayable on demand. There is no allowance for doubtful debts arising from these outstanding balances.

The Company's exposure to credit and currency risks, and impairment losses for shareholder loan receivable are disclosed in Note 11.

Reconciliation of movements in liabilities to cash flows arising from financing activities

	Shareholder loans payable	
	2020	2019
	US\$'000	US\$'000
At 1 January	–	1,961,230
Changes from financing cash flows		
Proceeds from/(Settlement of) loans due to shareholders	401,693	(1,961,230)
At 31 December	401,693	–

7 Share capital

	2020	2019
	No. of shares	No. of shares
Fully paid ordinary shares:		
At 1 January and 31 December	1	1
Fully paid preference shares:		
At 1 January	2,998,956,203	–
Issued for cash	329,501,867	3,046,016,658
Redemption of shares	–	(47,060,455)
At 31 December	3,328,458,070	2,998,956,203

Ordinary shares

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company, unless voting by show of hands is applied according to the Company's Articles of Association.

Redeemable preference shares (“RPS”)

Fully paid preference share capital of the company as at reporting date comprises the following:

Class	Price per share	At	Net issued/ (redeemed)	At	Net issued/ (redeemed)	At
	USD	1 Jan 2019 Number of shares	during the year Number of shares	31 Dec 2019 Number of shares	during the year Number of shares	31 Dec 2020 Number of shares
A	1.00	–	190,751,794	190,751,794	–	190,751,794
B	1.00	–	128,230,490	128,230,490	–	128,230,490
C	1.00	–	83,734,694	83,734,694	–	83,734,694
D	1.00	–	777,029,936	777,029,936	–	777,029,936
E	1.00	–	178,646,732	178,646,732	–	178,646,732
F	1.00	–	142,196,660	142,196,660	–	142,196,660
G	1.00	–	153,395,506	153,395,506	4,292,955	157,688,461
H	1.00	–	206,988,352	206,988,352	–	206,988,352
I	1.00	–	89,700,000	89,700,000	–	89,700,000
J	1.00	–	221,898,681	221,898,681	–	221,898,681
K	1.00	–	201,500,000	201,500,000	–	201,500,000
L	1.00	–	357,483,358	357,483,358	–	357,483,358
M	1.00	–	102,500,000	102,500,000	–	102,500,000
N	1.00	–	164,900,000	164,900,000	–	164,900,000
O	1.00	–	–	–	325,208,912	325,208,912
		–	2,998,956,203	2,998,956,203	329,501,867	3,328,458,070

The holders of preference shares shall be entitled to receive distributions as well as participate in the surplus assets of the Company available for distribution from the Company’s direct and indirect ownership and investment interests in the investments indicated in the table below.

Redeemable preference shares (“RPS”)

Class of preference shares	Investment interests
Preference Class A shares	Hangzhou Kangji Medical
Preference Class B shares	Jetanin
Preference Class C shares	Project Hostel
Preference Class D shares	Du Xiaoman
Preference Class E shares	Greencross
Preference Class F shares	Sai Life Sciences
Preference Class G shares	Five Star
Preference Class H shares	Pathology Asia Holdings
Preference Class I shares	RR Kabel
Preference Class J shares	PAMEL/Apollo
Preference Class K shares	Jaywalk Media
Preference Class L shares	UPL Corporation Limited
Preference Class M shares	APM Monaco Limited
Preference Class N shares	Dream Cruises
Preference Class O shares	Jio Platforms Limited

The Company may at any time redeem any or all of the redeemable preference shares.

The holders of preference shares are entitled to receive preference dividends as declared from time to time but do not have the right to participate in any dividends declared for ordinary shareholders. The preference shares do not carry the right to vote at meetings of the Company.

Upon winding up of the Company, each redeemable preference shares shall have the right to repayment, by way of redemption, out of any net proceeds available after payment to all the creditors of the Company (whether secured or unsecured), of capital in priority to holders of ordinary shares of the Company, pro rata according to their holdings of redeemable preference shares.

8 Deferred tax liabilities

	Note	2020 US\$'000	2019 US\$'000
At 1 January		–	–
Net provision made during the year	9	36,748	–
At 31 December		<u>36,748</u>	<u>–</u>

Deferred tax liabilities are attributable to the following:

	2020 US\$'000	2019 US\$'000
Investments at fair value through profit or loss	<u>36,748</u>	<u>–</u>

9 Tax expense

	Note	2020 US\$'000	2019 US\$'000
Deferred tax expense			
Origination and reversal of temporary differences	8	36,748	–
Total deferred tax expense		<u>36,748</u>	<u>–</u>

Reconciliation of effective tax rate

Profit before tax	<u>766,956</u>	<u>305,631</u>
Tax using Singapore tax rate of 17% (2019: 17%)	130,383	51,957
Effect of tax incentive schemes	(130,383)	(51,957)
Effect of tax rates in foreign jurisdictions	36,748	–
	<u>36,748</u>	<u>–</u>

The Company was approved by the Monetary Authority of Singapore for the Tax Exemption Scheme for Resident Funds from 16 November 2017. The tax exemption status will be for the life of the Company, provided the Company continues to meet all conditions and terms set out in MAS circular - FDD Circular 06/2014, and the relevant Income Tax legislations.

10 Related party transactions

Other than those disclosed elsewhere in the financial statements, transactions with related parties are as follows:

	2020	2019
	US\$'000	US\$'000
Related party transaction		
Management fees expense	3,174	2,455

Key management personnel

None of the directors earned any directors' fees or other remuneration in respect of their appointments as directors of the Company during the current year and prior year. The directors are not paid directly by the Company but receive remuneration from the Company's management company (a related corporation). No apportionment has been made as the services provided by these directors to the Company are incidental to their responsibilities to the management company.

11 Classification of financial instruments

	At FVTPL	Amortised	Other	Total
	US\$'000	cost	financial	carrying
	US\$'000	US\$'000	liabilities	amount
	US\$'000	US\$'000	US\$'000	US\$'000
2020				
Investments at fair value through profit or loss	4,884,872	–	–	4,884,872
Amounts due from related parties	–	25,137	–	25,137
Shareholder loan receivable	–	2,745	–	2,745
Cash and cash equivalents	–	5,196	–	5,196
	<u>4,884,872</u>	<u>33,078</u>	<u>–</u>	<u>4,917,950</u>
Other payables	–	–	319	319
Shareholder loans payable	–	–	401,693	401,693
Accrued expenses	–	–	658	658
Amounts due to related parties	–	–	29,926	29,926
	<u>–</u>	<u>–</u>	<u>432,596</u>	<u>432,596</u>

	At FVTPL US\$'000	Amortised cost US\$'000	Other financial liabilities US\$'000	Total carrying amount US\$'000
2019				
Investments at fair value through profit or loss	3,381,999	–	–	3,381,999
Amounts due from related parties	–	19,959	–	19,959
Shareholder loan receivable	–	2,745	–	2,745
Cash and cash equivalents	–	5,553	–	5,553
	<u>3,381,999</u>	<u>28,257</u>	<u>–</u>	<u>3,410,256</u>
Other payables	–	–	109	109
Amounts due to related parties	–	–	21,251	21,251
	<u>–</u>	<u>–</u>	<u>21,360</u>	<u>21,360</u>

12 Financial risk management

The Company has exposure to the following risks from its use of financial instruments:

- credit risk
- liquidity risk
- foreign currency risk
- interest rate risk
- other market price risk

This note presents information about the Company's objectives, policies and processes for measuring and managing risk, the Company's exposure to each of the above risks, and the Company's management of capital. Further quantitative disclosures are included throughout these financial statements.

Risk management framework

Risk management is integral to the whole business of the Company. The Company has a system of controls in place to create an acceptable balance between the cost of risks occurring and the cost of managing the risks. The management continually monitors the Company's risk management process to ensure that an appropriate balance between risk and control is achieved. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities.

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's receivables from its investments.

The Company has no significant concentrations of credit risk and has established policies to minimise such risk.

At the reporting date, the Company's maximum exposure to credit risk is represented by the carrying amount of each class of financial assets recognised in the statement of financial position.

The Company holds non-trade receivables from related parties. These balances are amounts lent to related parties to satisfy short term funding requirements relating to its underlying investments. Based on an assessment of qualitative and quantitative factors that are indicative of the risk of default (including but not limited to external ratings, audited financial statements, management accounts and cash flow projections, and available press information, if available, and applying experienced credit judgement), these exposures are considered to have low credit risk. Therefore, impairment on these balances has been measured on the 12-month expected credit loss basis; and the amount of the allowance is insignificant.

Impairment on cash and cash equivalents has been measured on the 12-month expected loss basis and reflects the short maturities of the exposures. The Company considers that its cash and cash equivalents have low credit risk based on the external credit ratings of the counterparties.

There are no financial assets that are past due or impaired, or would otherwise be past due and not impaired as at 31 December 2020 and 31 December 2019.

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset.

The Company monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by management to finance the Company's operations and to mitigate the effects of fluctuations in cash flows through management of working capital.

The Company's exposure to liquidity risk is set out below.

The following are the contractual maturities of financial liabilities, excluding the impact of netting agreements.

	Carrying amount US\$'000	Cash flows		
		Contractual cash flows US\$'000	Within 1 year US\$'000	Between 1 to 5 years US\$'000
2020				
Non-derivative financial liabilities				
Shareholder loan payable	401,693	401,693	401,693	
Accrued expenses	658	658	658	
Other payables	319	319	319	–
Amounts due to related parties	29,926	29,926	29,926	–
	<u>432,596</u>	<u>432,596</u>	<u>432,596</u>	<u>–</u>
2019				
Non-derivative financial liabilities				
Other payables	109	109	109	–
Amounts due to related parties	21,251	21,251	21,251	–
	<u>21,360</u>	<u>21,360</u>	<u>21,360</u>	<u>–</u>

Foreign currency risk

Foreign currency risk is the risk that arises from the change in price of one currency against another because of changes in foreign currency exchange rates.

The Company invests in assets that are denominated in currencies other than its functional currency, the USD. Consequently, the Company is exposed to risks that the exchange rate of the USD relative to other currencies may change in a manner which has an adverse effect on the reported value of that portion of the Company's assets and liabilities which are denominated in currencies other than the USD.

As deemed necessary, the Company has the ability to enter into hedge agreements to minimise such risk.

The Company's exposure to foreign currency risk is set out below.

	Australian dollar US\$'000	China yuan US\$'000	Thai baht US\$'000	Indian rupee US\$'000	Singapore dollar US\$'000	Myanmar kyat US\$'000	Hong Kong Dollar US\$'000
2020							
Investments at fair value through profit or loss	448,480	1,591,833	146,664	1,178,355	697,633	297,800	524,107
Cash and cash equivalents	-	-	-	-	136	-	-
	<u>448,480</u>	<u>1,591,833</u>	<u>146,664</u>	<u>1,178,355</u>	<u>697,769</u>	<u>297,800</u>	<u>524,107</u>
2019							
Investments at fair value through profit or loss	181,609	1,381,505	126,102	888,600	266,600	274,900	262,683
Cash and cash equivalents	1	-	-	-	-	-	-
	<u>181,610</u>	<u>1,381,505</u>	<u>126,102</u>	<u>888,600</u>	<u>266,600</u>	<u>274,900</u>	<u>262,683</u>

Sensitivity analysis

A strengthening of USD by 5% against the following currencies at 31 December would have decreased profit or loss (before any tax effects) by the amounts shown below. This analysis is based on foreign currency exchange rate variances that the Company considered to be reasonably possible at end of the reporting period. The analysis assumes that all other variables, in particular interest rates, remain constant.

	Effect on profit/(loss) before tax	
	2020 US\$'000	2019 US\$'000
Australian dollar	22,424	9,080
Chinese yuan	79,592	69,075
Thai baht	7,333	6,305
Indian rupee	58,918	44,430
Singapore dollar	34,888	13,330
Myanmar kyat	14,890	13,745
Hong Kong Dollar	<u>26,205</u>	<u>13,134</u>

A weakening of USD against the above currencies at 31 December would have had the equal but opposite effect on the above currencies to the amounts shown above, on the basis that all other variables remain constant.

Interest rate risk

The Company does not account for any fixed rate financial assets and liabilities at fair value through profit or loss, and the Company does not designate derivatives (interest rate swaps) as hedging instruments under a fair value hedge accounting model. Therefore, the Company is not subject to significant exposure to interest rate risk.

Other market price risk

Equity price risk is the risk of potential adverse changes to the value of the investment in securities because of changes in market conditions such as volatility in security prices. Debt price risk is the risk of potential adverse changes to the value of the investment in securities because of changes in market conditions such as volatility in interest rates.

The Company's investments, with the exception of Hangzhou Kangji Medical, are not publicly traded are not publicly traded. The sensitivity of changes in fair value arising from alternative inputs is set out in Note 13.

A 5% increase in the share price of the following investments would have increased profit or loss (before any tax effects) by the amounts shown below, arising as a result of an increase in the fair value of the investments. The analysis assumes that all other variables remain constant.

	Effect on profit/(loss)	
	before tax	
	2020	2019
	US\$'000	US\$'000
Hangzhou Kangji Medical	17,369	12,674

A 5% decrease in the share price would have had the equal but opposite effect on the above investments by the amounts shown above, on the basis that all other variables remain constant.

Capital management

The primary objective of the Company's capital management is to ensure that it maintains healthy capital ratios in order to support its business and maximise shareholders' value.

The Company manages its capital structure which comprises all components of equity (i.e., share capital and accumulated profits) and makes alignment to it, in light of changes in economic conditions. To maintain or adjust the capital structure, the Company may align the dividend payment to shareholders, return capital to shareholders or issue new shares.

There were no changes in the Company's approach to capital management during the year.

The Company is not subject to externally imposed capital requirements.

13 Fair value of financial instruments

Fair values

The fair value of a financial instrument is the amount at which the instrument could be exchanged or settled between knowledgeable and willing parties in an arm's length transaction, other than in a forced or liquidation sale.

Equity securities and debt securities that are designated as financial assets at fair value through profit or loss are stated at their fair value.

Investments in publicly-traded securities are valued at quoted market prices based upon the last sales price on the measurement date. Discounts are applied, where appropriate, to reflect restrictions on the marketability of the investment.

When observable prices are not available for the Company's investments, the company uses the market and income approaches to determine fair value. The market approach consists of utilising observable market data (e.g., current trading and/or acquisition multiples) of comparable companies and applying it to a key financial metric (e.g., EBITDA) of the investee company. The comparability of the identified set of comparable companies to the investee company, among other factors, is considered in the application of the market approach.

The Company, depending on the type of investment or stage of the investee company's lifecycle, may also utilise a discounted cash flow analysis, an income approach, in combination with the market approach in determining fair value of the Company's investments. The income approach involves discounting projected cash flows of the investee company at a rate commensurate with the level of risk associated with those cash flows. Market participant assumptions are used in the determination of the discount rate.

In applying valuation techniques used in the determination of fair value, the Company assumes a reasonable period of time for liquidation of the investment, and takes into consideration the financial condition and operating results of the underlying portfolio company, nature of the investment, restrictions on marketability, holding period, market conditions, foreign currency exposures, and other factors the Company deems appropriate. In determining the fair value of the Company's investments, the Company exercises significant judgement and use the best information available as of the measurement date. Due to the inherent uncertainty of valuations, the fair values reflected in the accompanying financial statements may differ materially from values that would have been used had a readily available market for the investments existed.

The carrying amounts of financial assets and financial liabilities with a maturity of less than one year are assumed to approximate their fair values because of the short period to maturity.

Fair value hierarchy

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

Level 1: Quoted price (unadjusted) in an active market for an identical instrument.

Level 2: Valuation techniques based on observable inputs, either directly (i.e. as prices) or indirectly (i.e. derived from prices). This category includes instruments valued using: quoted prices in active markets for similar instruments; quoted prices for identical or similar instruments in markets that are considered less than active; or other valuation techniques for which all significant inputs are directly or indirectly observable from market data.

Level 3: Valuation techniques using significant unobservable inputs. This category includes all instruments for which the valuation technique includes inputs not based on observable data and the unobservable inputs have a significant effect on the instrument's valuation. This category includes significant instruments that are valued based on quoted prices for similar instruments for which significant unobservable adjustments or assumptions are required to reflect differences between the instruments.

In some cases, the inputs used to measure fair value might fall in different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the financial instrument in its entirety falls is determined based on the lowest level input that is significant to the valuation of the financial instrument in its entirety. Assessing the significance of a particular input to the financial instrument in its entirety requires judgement, and considers factors specific to the financial instrument.

The following table summarises the investments within the valuation hierarchy:

	Level 1 US\$'000	Level 2 US\$'000	Level 3 US\$'000	Total US\$'000
2020				
Financial assets at fair value through profit or loss	347,384	–	4,537,488	4,884,872
2019				
Financial assets at fair value through profit or loss	–	–	3,381,999	3,381,999

Level 3 fair values

The following table shows a reconciliation from the beginning balances to the ending balances for fair value measurements in Level 3 of fair value hierarchy:

	2020 US\$'000	2019 US\$'000
Investments at fair value through profit or loss		
At 1 January	3,381,999	2,016,349
Transfers out of Level 3	(253,472)	21,800
Total change in fair value gain included in profit or loss	559,784	304,253
Purchase of investments	932,477	1,060,142
Proceeds from disposal of investments	(83,300)	(24,823)
Net gain on disposal of investment	–	4,278
At 31 December	4,537,488	3,381,999
Total change in fair value gain included in profit or loss related to investments held at the end of the reporting year	559,784	304,253

Refer to Note 4 for more information on the investments.

Refer to Note 12 – other market price risk for the market price information of the investments.

Significant unobservable inputs used in measuring fair value

The table below sets out information about significant unobservable inputs used at 31 December 2020 in measuring financial instruments categorised as Level 3 in the fair value hierarchy.

2020	Fair value US\$'000	Valuation technique(s)	Unobservable input(s)	Actual input(s)	Range (weighted average)
APM Monaco	164,500	Market Comparables	LTM EBITDA Multiple	13.0x	12.0x - 14.0x
Aviva Singlife	229,693	Last Transaction Price	Operating and Market Performance	N/A	N/A
Dream Cruises	30,400	Last Transaction Price	Operating and Market Performance	N/A	N/A
Du Xiaoman	985,194	Market Comparables	Price / LTM Revenue Multiple	4.5x	3.5x - 5.5x
Five Star	226,900	Market Comparables	Book Value Multiple	3.5x	2.5x - 4.5x
Greencross	448,480	Market Comparables	LTM EBITDA Multiple	10.5x	9.5x - 11.5x
Jaywalk Studio Ltd.	168,511	Market Comparables	LTM Net Income	22.0x	21.0x - 23.0x
Jetanin	152,910	Market Comparables	LTM EBITDA Multiple	12.3x	11.3x - 13.3x
Jio Platforms Limited	325,155	Last Transaction Price	Operating and Market Performance	N/A	N/A
PAMEL/Apollo	297,800	Market Comparables	LTM EBITDA Multiple	13.5x	12.5x - 14.5x
Pathology Asia Holdings	467,940	Market Comparables	LTM EBITDA Multiple	14.0x	13.0x - 15.0x
Project Hostel	90,744	Market Comparables	Per Square Meter	47,000	45,000-49,000
Reliance Retail Ventures	250,842	Last Transaction Price	Operating and Market Performance	N/A	N/A
RR Kabel	81,400	Market Comparables	LTM EBITDA Multiple	13.0x	12.0x - 14.0x
Sai Life Sciences	206,300	Market Comparables	LTM EBITDA Multiple	18.0x	17.0x - 19.0x
Shanghai Bio-heart Biological Technology	45,000	Last Transaction Price	Operating and Market Performance	N/A	N/A
UPL Corporation	338,600	Market Comparables	LTM EBITDA Multiple	11.0x	10.0x - 12.0x
Zhaoke Ophthalmology	35,000	Last Transaction Price	Operating and Market Performance	N/A	N/A

2019	Fair value US\$'000	Valuation technique(s)	Unobservable input(s)	Actual input(s)	Range (weighted average)
Du Xiaoman	845,623	Market comparables	LTM revenue multiple	4.5x	3.5x-6.5x
Five Star	202,100	Last transaction price	Operating and market performance	N/A	N/A
Greencross	181,609	Last transaction price	Operating and market performance	N/A	N/A
Hangzhou Kangji Medical	253,472	Market comparables	LTM net income multiple	29.0x	28.0x-30.0x
Jaywalk Media	199,500	Last transaction price	Operating and market performance	N/A	N/A
Jetanin	126,102	Market comparables	LTM EBITDA multiple	17.5x	16.5x-18.5x
PAMEL / Apollo	274,900	Market comparables	LTM EBITDA multiple	14.0x	13.0x-15.0x
Pathology Asia Holdings	266,600	Market comparables	LTM EBITDA multiple	14.0x	13.0x-15.0x
Project Hostel	82,910	Market comparables	Per square meter	45,000	N/A
RR Kabel	91,700	Market comparables	LTM EBITDA multiple	14.25x	13.25x-15.25x
Sai Life Sciences	155,400	Market comparables	LTM EBITDA multiple	16.0x	15.0x-17.0x
APM Monaco	97,842	Last transaction price	Operating and market performance	N/A	N/A
Dream Cruises	164,841	Last transaction price	Operating and market performance	N/A	N/A
UPL Corporation Limited	439,400	Market comparables	LTM EBITDA multiple	11.5x	10.5x-12.5x

- EBITDA, Revenue, Per Square Meter, and net income multiples: Represents amounts that market participants would use when pricing investments. EBITDA, Revenue, Per Square Meter, and net income multiples are selected by management based on a relative comparison of the subject company to comparable public companies based on geographical location, industry, size, target markets, marketability and other factors that management considers to be reasonable. The traded multiples for the comparable companies are determined by dividing the enterprise value of the company by its EBITDA, Per Square Meter, or revenue. The EBITDA, Revenue, and Net Income metrics used in the valuation may be based on last twelve months (“LTM”) or forward (“FWD”) looking data.
- Book value multiples: Represents amounts that market participants would use when pricing investments. Book value multiples are selected by management based on a relative comparison of the subject company to comparable public companies based on geographical location, industry, size, target markets, marketability and other factors that management considers to be reasonable. The traded multiples for the comparable companies are determined by dividing the enterprise value of the company by its book value.
- Latest price: Represents the time since a market transaction of the investment was observed. There are no unobservable inputs since the investment is measured at the latest transaction price. As a result, there are no unobservable inputs that have been internally developed by the Company when determining fair value.

Although the Company believes that its estimates of fair value are appropriate, the use of different methodologies or assumptions could lead to different measurements of fair value. For fair value measurements in Level 3 investments, changing one or more of the assumptions used to reasonably possible alternative assumptions would have the following effects on the net assets of the Company.

	Unobservable input(s)	Increase in unobservable inputs	Favourable impact on profit and loss US\$'000	(Decrease) in unobservable inputs	Unfavourable impact on profit and loss US\$'000
2020					
APM Monaco	LTM EBITDA Multiple	+1.0x	14,621	-1.0x	(14,621)
	Price / LTM Revenue Multiple				
Du Xiaoman	Multiple	+1.0x	208,255	-1.0x	(208,255)
Five Star	Book Value Multiple	+1.0x	64,829	-1.0x	(64,829)
Greencross	LTM EBITDA Multiple	+1.0x	57,440	-1.0x	(57,440)
Jaywalk Studio Ltd.	LTM Net Income	+1.0x	5,761	-1.0x	(5,761)
Jetanin	LTM EBITDA Multiple	+1.0x	12,354	-1.0x	(12,354)
PAMEL/Apollo	LTM EBITDA Multiple	+1.0x	36,493	-1.0x	(36,493)
Pathology Asia Holdings	LTM EBITDA Multiple	+1.0x	42,244	-1.0x	(42,244)
Project Hostel	Per Square Meter	+2.0x	7,829	-2.0x	(7,829)
RR Kabel	LTM EBITDA Multiple	+1.0x	6,510	-1.0x	(6,510)
Sai Life Sciences	LTM EBITDA Multiple	+1.0x	12,429	-1.0x	(12,429)
UPL Corporation	LTM EBITDA Multiple	+1.0x	59,285	-1.0x	(59,285)
2019					
Du Xiaoman	LTM Revenue Multiple	+2.0x	373,065	-1.0x	(189,406)
Hangzhou Kangji Medical (Equity)	FWD Net Income	+1.0x	687	-1.0x	(16,257)
Jetanin	LTM EBITDA Multiple	+1.0x	22,285	-1.0x	(3,453)
PAMEL/Apollo	FWD EBITDA Multiple	+1.0x	31,722	-1.0x	(31,474)
Pathology Asia Holdings	LTM EBITDA Multiple	+1.0x	22,580	-1.0x	(22,580)
RR Kabel	LTM EBITDA Multiple	+1.0x	6,813	-1.0x	(6,813)
Sai Life Sciences	LTM EBITDA Multiple	+1.0x	10,125	-1.0x	(10,125)
UPL Corporation	LTM EBITDA Multiple	+1.0x	59,571	-1.0x	(59,571)

14 Subsequent events

Issuance of preference shares

During the period of January 2021 – April 2021, the Company issued the following preference shares or a cash consideration of US \$672,809,466.

	No. of shares	US\$
Preference Class P shares	45,700,000	45,700,000
Preference Class R shares	35,700,152	35,700,152
Preference Class S shares	252,062,284	252,062,284
Preference Class T shares	308,500,000	308,500,000
Preference Class U shares	30,847,030	30,847,030
	<u>672,809,466</u>	<u>672,809,466</u>